secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001628280-23-037446
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Q3 2023: net loss $1.0M, revenue $10.1M, YTD adj. EPS $0.29
----------------------------------------------------------------------

- Net loss of $1.0M; adjusted earnings $260K ($0.02/share); YTD net income $15K, adj. EPS $0.29.
- Product revenue $10.1M (Kristalose $3.9M, Vibativ $2.8M, Sancuso $1.9M, Caldolor $1.2M).
- New $25M revolving credit facility with Pinnacle Bank; $12.9M drawn at quarter-end.
- Sancuso acquisition transition completed; FDA approved new mfg plant; supplies underway Q4 2023.
- NOPAIN Act may provide separate Medicare reimbursement for Caldolor from 2025; ifetroban Phase II trials ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/0001628280-23-037446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023037446/cpix-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer